Cargando…
Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines
Large-scale deployment of safe and durably effective vaccines can curtail the coronavirus disease-2019 (COVID-19) pandemic. However, the high vaccine efficacy (VE) reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about 2 months, and thus does...
Autores principales: | Lin, Dan-Yu, Zeng, Donglin, Gilbert, Peter B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989522/ https://www.ncbi.nlm.nih.gov/pubmed/33693529 http://dx.doi.org/10.1093/cid/ciab226 |
Ejemplares similares
-
Evaluating the Efficacy of Coronavirus Disease 2019
Vaccines
por: Lin, Dan-Yu, et al.
Publicado: (2020) -
Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019
por: Lin, Dan-Yu, et al.
Publicado: (2020) -
Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Lin, Dan-Yu, et al.
Publicado: (2021) -
Coronavirus disease 2019 and its vaccines: An update
por: Jeddy, Nadeem, et al.
Publicado: (2021) -
Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?
por: Chamilos, Georgios, et al.
Publicado: (2020)